23andMe has said it wants to allow new bids by both parties with a deadline of 12th June, according to a Financial Times ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & ...

A combination regimen based on Pfizer's BRAF inhibitor Braftovi achieved a 51% reduction in the risk of death in patients ...

Giusy Di Conza, head of research at small molecule cancer therapeutics firm iOnctura, said ADCs were “heralding a shift ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Sanofi has been given a reprimand by the UK's Prescription Medicines Code of Practice Authority (PMCPA), after admitting that ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...